^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Breast Cancer
    Drug:fexagratinib (ABSK091) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A study of AZD4547 in patients with tumours having high number of copies of the FGFR1 or FGFR2 gene.

    Excerpt:
    ...― FGFR1 or FGFR2 amplification as assessed by AZ approved laboratory. ...
    Trial ID:
    2011-003718-18
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours

    Excerpt:
    ...- FGFR1 amplification Advanced squamous cell lung cancer...
    Trial ID:
    NCT01795768
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

    Excerpt:
    Eight patients with FGFR1-amplified breast cancer and 9 with FGFR2-amplified gastroesophageal cancer were treated with AZD4547 in a translational clinical trial (Supplementary Fig. S1A). One FGFR1-amplified (12.5% response rate) and 3 FGFR2-amplified (33% response rate) patients had confirmed responses to AZD4547 (Fig. 1A and B), reaching the predefined criteria for efficacy in the FGFR2-amplified cohort.
    DOI:
    10.1158/2159-8290.CD-15-1246